Navigation Links
ZymoGenetics Reports Results From Atacicept Phase 1b Clinical Trial,in B-Cell Chronic Lymphocytic Leukemia

looking statements are based on the current intent and expectations of the management of ZymoGenetics. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict. ZymoGenetics' actual results and the timing and outcome of events may differ materially from those expressed in or implied by the forward-looking statements because of risks associated with our unproven discovery strategy, preclinical and clinical development, regulatory oversight, intellectual property claims and litigation and other risks detailed in the company's public filings with the Securities and Exchange Commission, including the company's Annual Report on Form 10-K for the year ended December 31, 2006. Except as required by law, ZymoGenetics undertakes no obligation to update any forward-looking or other statements in this press release, whether as a result of new information, future events or otherwise.

    Contact

    Investor Relations                          Media Relations

    John Calhoun, MD, MBA                       Susan W. Specht, MBA

    Director, Corporate Communications &        Associate Director, Corporate

     Investor Relations                          Communications

    (206) 442-6744                              (206) 442-6592

CONTACT: investors, John Calhoun, MD, MBA, Director, CorporateCommunications & Investor Relations, +1-206-442-6744, or media, Susan W.Specht, MBA, Associate Director, Corporate Communications, +1-206-442-6592both of ZymoGenetics, Inc.

Web site: http://www.zymogenetics.com//

Ticker Symbol: (NASDAQ-NMS:ZGEN)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Page: 1 2 3

Related medicine technology :

1. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
2. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
3. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
4. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
5. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
6. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
7. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
8. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
9. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
10. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
11. Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia
Post Your Comments:
(Date:8/27/2014)... , Aug. 27, 2014 IRIDEX Corporation (NASDAQ: ... James H. Mackaness is scheduled to make an investor ... at 2:55 p.m. Eastern Time on Wednesday, September 3, in ... of the investor presentation will be available in the Investors ... About IRIDEX IRIDEX Corporation was founded ...
(Date:8/27/2014)... Aug. 27, 2014   Auxilium Pharmaceuticals , Inc. (NASDAQ: ... company, today announced that certain members of the executive ... Conference to be held September 8-10, 2014 in ... Chief Executive Officer and President, is scheduled to present ... at 10:55 a.m. ET on Wednesday, September 10, 2014. ...
(Date:8/27/2014)... 27, 2014 Asterias Biotherapeutics Inc. (OTCBB: ASTY) ... Administration (FDA) to initiate a Phase 1/2a clinical trial ... spinal cord injury.  The approved trial follows the successful ... product, and is designed to assess safety and activity ... cervical spinal cord injuries, the first targeted indication for ...
Breaking Medicine Technology:Auxilium Pharmaceuticals, Inc. To Present At The Morgan Stanley Healthcare Conference 2Auxilium Pharmaceuticals, Inc. To Present At The Morgan Stanley Healthcare Conference 3Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury 2Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury 3Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury 4Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury 5
(Date:8/27/2014)... August 27, 2014 Scientists at The Scripps ... a specific signaling pathway can be associated with alcohol ... a gene, called neurofibromatosis type 1 (Nf1), which TSRI ... The new research shows Nf1 regulates gamma-aminobutyric acid (GABA), ... relaxation. , "This novel and seminal study provides ...
(Date:8/27/2014)... Georgia State University’s Center for ... $600,000 grant from the Maternal and Child Health ... to support implementation of the Autism Plan for ... youth with autism spectrum disorder. , In preparing ... Advisory Council composed of key stakeholders from across ...
(Date:8/27/2014)... Foundation scientists examined the implications for cultural diversity ... rehabilitation. The article by Anthony Lequerica, PhD, and ... acquired brain injury (ABI) rehabilitation (doi:10.3233/NRE-141079) was ... and Krch are research scientists in Traumatic Brain ... for the Northern New Jersey TBI Model System. ...
(Date:8/27/2014)... significantly improve musculoskeletal and overall health, and minimize or ... of the latest research on senior athletes (ages 65 ... Journal of the American Academy of Orthopaedic Surgeons ... aging causes an inevitable deterioration of the body and ... of related injuries such as sprains, strains and fractures; ...
(Date:8/27/2014)... Will Holbrook, CP LP, has joined ... over 15 years of experience in the prosthetics field. ... with a Bachelor of Science degree with a major ... received his graduate degree in prosthetics at Northwestern University ... Will join us at Fourroux,” says Keith Watson, owner ...
Breaking Medicine News(10 mins):Health News:Scripps Research Institute scientists link alcohol-dependence gene to neurotransmitter 2Health News:Center for Leadership in Disability Awarded $600,000 Grant to Improve Services for Georgia’s Children and Youth with Autism 2Health News:Lifetime of fitness: A fountain of youth for bone and joint health? 2
... implants created using stem cells can only be constructed ... before the almost inevitable need for total joint replacement. ... investigating the possibilities of a biologically-engineered synthetic liquid polymer ... offering a one stop, permanent solution. ...
... caregivers to hospital patients, coordinating and providing direct care and delivering ... ensure that each of its patient-care units has an adequate number ... number of hours nurses work known as the "target level" ... flow of patients and their need for care. Too many nurses ...
... By Amanda Gardner HealthDay Reporter , WEDNESDAY, March ... target levels in a large hospital, more patients died, a ... an era of nursing shortages and cost-cutting, in that the ... authors of the research, appearing in the March 17 issue ...
... By Amanda Gardner HealthDay Reporter , ... the tsunami that devastated the nuclear complex in Japan ... that any radiation from the unfolding disaster across the ... say. The chances of any radioactive plume reaching ...
... Gardner HealthDay Reporter , WEDNESDAY, March 16 (HealthDay ... treatment to show a benefit for women with a rare ... even a treatment. The drug, sirolimus (Rapamycin), improved both ... lymphangioleiomyomatosis, or LAM, according to a study published online March ...
... recent study from North Carolina State University shows that while ... has grown, fund support for park operations has been significantly ... growth endangers the more than $20 billion in economic impact ... the reduction in general-fund support for operations puts stress on ...
Cached Medicine News:Health News:Liquid biomaterials take stem cell therapy to new level 2Health News:Risk of hospital patient mortality increases with nurse staffing shortfalls, study finds 2Health News:Risk of hospital patient mortality increases with nurse staffing shortfalls, study finds 3Health News:When Nurse Staffing Drops, Mortality Rates Rise: Study 2Health News:Radiation From Japan's Nuke Disaster Unlikely to Threaten U.S., Experts Say 2Health News:Radiation From Japan's Nuke Disaster Unlikely to Threaten U.S., Experts Say 3Health News:Radiation From Japan's Nuke Disaster Unlikely to Threaten U.S., Experts Say 4Health News:Transplant Drug May Fight Rare Lung Disorder 2Health News:Transplant Drug May Fight Rare Lung Disorder 3Health News:Study shows attendance at state parks grows, even as funding decreases 2
... ultra versatile model angulates for vascular ... the height of the support leg, ... post, or double tee foot. Add ... comfort and stability. A convenient bracket ...
... RX600 is a versatile, fully powered orthopaedic ... built-in traction facilities, a powered centre break ... extremely versatile too. ,<br.,In fact the RX600 ... as it is for traction procedures. The ...
... OL1000 Bone Growth Stimulators are portable, battery-powered ... noninvasive treatment of an established nonunion fracture ... and flat bones. , ... of healing of 60.7% in patients with ...
... The EBI OsteoGen surgically implanted bone growth ... of nonunions when surgery is already planned or ... the OsteoGen is totally surgically implanted, patients are ... site 24 hours a day for up to ...
Medicine Products: